Press Releases about Theralase Technologies Inc
Theralase(R) Granted Canadian Cancer Vaccine Patent
April 05, 2024
Via ACCESSWIRE
Theralase(R) Release's 4Q2023 Interim Financial Statements
March 27, 2024
Via ACCESSWIRE
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
October 23, 2023
Via ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 16, 2023
Via ACCESSWIRE
Theralase(R) Files US Patent for Enhanced Immunotherapy
October 05, 2023
Via ACCESSWIRE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
February 05, 2024
Via ACCESSWIRE
Via ACCESSWIRE
Theralase Release’s 3Q2023 Interim Financial Statements
November 29, 2023
Via ACCESSWIRE
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
November 29, 2023
Via ACCESSWIRE
Theralase(R) Announces Brokered LIFE Financing
October 23, 2023
Via ACCESSWIRE
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
September 29, 2023
Via ACCESSWIRE
Via ACCESSWIRE
Theralase(R) Grants Stock Options
September 21, 2023
Via ACCESSWIRE
Theralase(R) Closes Private Placement Equity Financing
September 07, 2023
Via ACCESSWIRE
Theralase Release’s 2Q2023 Interim Financial Statements
August 29, 2023
Via ACCESSWIRE
Via ACCESSWIRE
Via ACCESSWIRE
Via ACCESSWIRE
Theralase Release FY2020 Audited Financial Statements
April 28, 2021
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.